Pulse Biosciences, Inc. (PLSE) is a novel bioelectric medicine company dedicated to improving the lives of patients battling a variety of conditions. The company is committed to progress clinical applications that address significant unmet medical needs and carries forward vast potential in immuno-oncology.
Founded in 2014 and based in Hayward, California, Pulse Biosciences, Inc is focused on developing and commercializing a platform using its proprietary "Nano-Pulse Stimulation" (NPS) technology. The NPS is a non-thermal, precise and localized technology that opens up new doors for medical advances. It’s designed to initiate cell death in the treatment of various types of solid tumors while sparing neighboring healthy tissue, hence becoming an innovative solution in the healthcare industry.
Pulse Biosciences, Inc places a significant emphasis on research and development. Their primary research focus revolves around using NPS technology to treat dermatological and aesthetic conditions as well as solid tumors. The company also examines the utility of NPS in additional applications, such as cardiac ablation and veterinary care.
The NPS technology platform by Pulse Biosciences has demonstrated encouraging results in several early trials in humans and animals. It has also been positively received by the scientific community, with many leading experts supportive of its potential.
One of the prominent applications of the NPS technology is CellFXTM, aimed at dermatology and aesthetics conditions. The CellFXTM system is used in procedures addressing sebaceous glands responsible for several dermatologic conditions such as sebaceous hyperplasia, acne, and skin rejuvenation.
Despite being relatively young, Pulse Biosciences, Inc has made a notable impact in the bioscience industry. The company’s mission of creating a distinct, clinically superior, operator-independent and patient-friendly tissue treatment methodology through its NPS technology is commendable. The diligence and commitment of Pulse Biosciences to continue its research and development efforts while maintaining its patient-focused mission symbolize a highly promising future for the company in the medical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Pulse Biosciences has announced the completion of enrollment for its PRECISE-BTN clinical study, which evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study successfully enrolled 100 patients across three U.S. sites, doubling its original target. The company plans to present preliminary data from the study at an upcoming medical conference, with full data expected after all patients complete their 12-month follow-up.
Pulse Biosciences (NASDAQ:PLSE) has successfully completed patient enrollment for its PRECISE-BTN clinical trial, which evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study expanded from 50 to 100 patients, with enrollment occurring at three U.S. clinical sites. The first patient has also completed their 12-month follow-up, and the trial will assess safety, nodule volume reduction, symptom relief, hormone normalization, and quality of life improvements.
Pulse Biosciences COO Liane Teplitsky recently purchased $99,971 worth of company stock through open market transactions. These purchases occurred as PLSE stock trades near its 52-week high after a significant year-to-date surge, though InvestingPro analysis suggests it may be overvalued. The company has also reported a wider-than-expected Q2 2026 loss but is making progress in clinical trials and has received positive analyst ratings.
Bank of America Corp DE has increased its stake in Pulse Biosciences, Inc (NASDAQ:PLSE) by 8.2% in the first quarter, now owning 866,061 shares worth over $18 million. Several other institutional investors also adjusted their positions in PLSE. The article also covers Pulse Biosciences' recent price performance, earnings, and analyst ratings, which currently indicate a "Moderate Buy" consensus.
Pulse Biosciences (PLSE) recently reported wider second-quarter losses and initiated a $75 million equity offering, despite a significant run-up in its share price. The company is advancing its atrial fibrillation nsPFA program, but its current valuation of $46.79 is considered overvalued compared to a narrative fair value of $41.00. Investors are advised to examine key reward and warning signs as the company faces hurdles like ongoing losses and execution risks in converting its pipeline into revenue.
Pulse Biosciences (PLSE) has granted equity awards to five new hires, totaling options for 16,950 shares, to attract talent crucial for advancing its medical device technologies. The company exhibits an extremely high Price-to-Sales ratio of 2755.9x, indicating strong market expectations despite its unprofitable and cash-flow-negative status. Its GF Score™ is 30/100, reflecting weak profitability and valuation, though tempered by moderate financial strength and strong momentum, while insider buying signals management confidence.